Indications
Zinplava is indicated for the prevention of recurrence of Clostridium difficile infection (CDI) in adults at high risk for recurrence of CDI.
Composition
- Active substance
- Bezlotoxumab
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Zinplava
- Active substance
- Bezlotoxumab
- ATC code
- J06BB21
- Therapeutic area
- Enterocolitis, Pseudomembranous
- Marketing authorisation holder
- Merck Sharp & Dohme B.V.
- Status
- Authorised
- EU authorisation
- 18 Jan 2017